Ruboxistaurin Topical Formulation for Low-Irritation Hyperpigmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperpigmentation, such as those using hydroquinone, are either minimally effective at safe concentrations or toxic at higher doses, and there is a lack of a topical formulation for PKC-β inhibitors like ruboxistaurin that is easily administered without skin irritation.
Innovation Solution
A composition comprising ruboxistaurin free base or its salts, combined with excipients such as organic solvents, penetration enhancers, antioxidants, and gelling agents, is developed to provide a non-irritating topical treatment for hyperpigmentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroquinone is used to treat hyperpigmentation, then melanin synthesis is inhibited, but skin toxicity occurs at high concentrations and minimal effectiveness is achieved at safe low concentrations
Solution Approach 1:
The patent changes the mechanism of action from hydroquinone's direct tyrosinase inhibition to PKC-β inhibition, which indirectly affects melanin synthesis. This parameter change in the target enzyme pathway allows for effective hyperpigmentation treatment without the toxic side effects associated with hydroquinone at effective concentrations.
Solution Approach 2:
The patent introduces PKC-β as an intermediary target between UV radiation and melanin synthesis. By inhibiting PKC-β, the pathway from UV exposure to melanin production is blocked, providing a safer alternative to direct tyrosinase inhibition while maintaining treatment effectiveness.
2Reliability
If PKC-β inhibitor (ruboxistaurin) is formulated topically, then selective inhibition of melanin production is achieved, but solubility and skin penetration issues arise
Solution Approach 1:
The patent uses penetration enhancers as intermediary substances that facilitate the delivery of ruboxistaurin through the skin barrier. These enhancers create temporary channels or modify the skin structure to allow the PKC-β inhibitor to reach its target in melanocytes without compromising safety.
Solution Approach 2:
The patent formulates a composite topical composition combining ruboxistaurin with penetration enhancers and other formulation additives. This composite approach addresses the solubility and penetration issues by creating a synergistic formulation that enhances drug delivery while maintaining the selective PKC-β inhibition mechanism.
3Reliability
If PKC-β inhibitor is applied topically, then hyperpigmentation is reduced, but skin irritation occurs
Solution Approach 1:
The patent optimizes the concentration parameters of ruboxistaurin in the topical formulation to achieve effective hyperpigmentation reduction while staying below irritation thresholds. By carefully controlling the dose parameter, the patent maintains therapeutic effectiveness without excessive skin irritation.
Solution Approach 2:
The patent introduces soothing excipients and penetration enhancers as intermediary substances that facilitate drug delivery while simultaneously reducing skin irritation. These additives act as mediators between the active ingredient and the skin, enabling effective treatment with minimal adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively inhibits melanin production, reducing hyperpigmentation with minimal skin irritation and maintaining stability over time.
Implementation Method 1
an organic solvent and/or a penetration enhancer
Implementation Method 2
an antioxidant
Implementation Method 3
a gelling agent
Data Source
AI summary
Provided herein are compositions comprising ruboxistaurin free base and its salts thereof and methods of use for treating conditions of the skin.